openPR Logo
Press release

Investigation for NASDAQ: SRPT Investors over potential Wrongdoing at Sarepta Therapeutics, Inc.

02-14-2020 06:33 PM CET | Politics, Law & Society

Press release from: Shareholders Foundation

An investigation on behalf of current long term investors in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) shares.

An investigation on behalf of current long term investors in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) shares.

An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Sarepta Therapeutics, Inc..

Investors who are current long term investors in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ: SRPT stocks follows a lawsuit filed against Sarepta Therapeutics, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: SRPT stocks, concerns whether certain Sarepta Therapeutics, Inc. directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the Southern District of New York the plaintiff alleges that the Defendants made false and/or misleading statements and/or failed to disclose that golodirsen posed significant safety risks to patients, that consequently, the NDA package for golodirsen's accelerated approval was unlikely to receive FDA approval, and that as a result, Sarepta's public statements were materially false and misleading at all relevant times.

Those who purchased shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation for NASDAQ: SRPT Investors over potential Wrongdoing at Sarepta Therapeutics, Inc. here

News-ID: 1933210 • Views: 569

More Releases from Shareholders Foundation

Investigation announced for Investors in NYSE: NOVA shares over potential Wrongd …
An investigation on behalf of investors in shares of Sunnova Energy International Inc. (NYSE: NOVA) was announced over potential breaches of fiduciary duties by certain officers and directors at Sunnova Energy International Inc. Investors who purchased shares of Sunnova Energy International Inc. (NYSE: NOVA) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Sunnova Energy
Investigation for Investors in E*TRADE Financial Corporation (NASDAQ: ETFC) over …
An investigation was announced concerning whether the takeover of E*TRADE Financial Corporation is unfair to NASDAQ: ETFC stockholders. Investors who purchased shares of E*TRADE Financial Corporation (NASDAQ: ETFC) and currently hold any of those NASDAQ: ETFC shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain officers and directors of E*TRADE Financial Corporation breached their
Investigation announced for Long Term Investors in shares of Altria Group, Inc. …
Certain directors of Altria Group, Inc are under investigation concerning potential breaches of fiduciary duties. Investors who are current long term investors in Altria Group, Inc. (NYSE: MO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for investors in NYSE: MO stocks follows a lawsuit filed against Altria Group, Inc. over alleged securities laws violations.
Investigation announced for Long-Term Investors in NASDAQ: MDXG shares over poss …
An investigation was announced concerning possible breaches of fiduciary duties by certain directors at MiMedx Group Inc. Investors who purchased shares of MiMedx Group Inc (NASDAQ: MDXG) and currently hold any of those NASDAQ: MDXG shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain MiMedx Group directors breached their fiduciary duties and caused damage

All 5 Releases


More Releases for Sarepta

Muscular Dystrophy Treatment Market: Growth, Development, Demand and Forecast 20 …
Muscular Dystrophy is characterized by a collection of muscle-wasting conditions. The disorder is caused by genetic mutations which interfere with the production of muscle protein dystrophin, necessary to build muscles. Muscular dystrophy is a genetic disease, consequently, the chance of an individual developing a disease increases with a history of muscular dystrophy in the family. The symptoms include shortening of muscles and tendons, the curvature of spine, weakening of heart
Duchenne Muscular Dystrophy Treatment Market Development Factors with Top Player …
Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness. DMD is caused due to alteration in gene sequence coding for dystrophin protein, which is present the muscle. It is a rare muscle disease which majorly affects males. The symptoms includes intellectual disability, muscle weakness and, difficulty in walking and breathing. Congestive heart failure, mental impairment, pneumonia or respiratory failure are some of the
Dystrophin Market to Reach USD 13.02 Billion By 2026 | Top Vendors: Solid Biosci …
According to the current analysis of Reports and Data, the global Dystrophin Market was valued at 0.60 billion in 2018 and is expected to reach USD 13.02 billion by year 2026, at a CAGR of 47% percent. The growth of the dystrophin market is more in countries such as U.S, Austria, Czech Republic, Denmark, Germany, Hungary, Israel, Italy, Norway, Portugal, Slovakia, South Korea, and the United Kingdom; where key muscular
Duchenne Muscular Dystrophy Market Analysis By 2026 | Top Key Players are Sarept …
As per the report by Persistence Market Research (PMR), the global duchenne muscular dystrophy market is expected to experience strong growth. The market is also estimated to expand at a CAGR of 48.3% during the forecast period. The global duchenne muscular dystrophy market is estimated to bring in US$ 10,664.5 million revenue by the end of 2026. To know key findings Request Sample Report @: https://www.persistencemarketresearch.com/samples/12475 Duchenne Muscular Dystrophy (DMD) is a
Antisense Oligonucleotides Market Growth Focusing on Trends & Innovations: Analy …
Antisense oligonucleotides (ASOs) are 15–25 nt oligonucleotides designed to tie complementary RNA targets for the degradation. They are synthesized so that they can be used to block disease processes by altering the synthesis of a specific protein. ASOs offers promising treatment options for a range of medical disorders. They facilitate the development of therapeutics affecting protein targets which cannot be treated with protein therapeutics. They can target a particular malfunctioning
Antisense Oligonucleotides Market to Gain a Stronghold by 2027 || Ionis Pharmace …
Antisense oligonucleotides (ASOs) are 15–25 nt oligonucleotides designed to tie complementary RNA targets for the degradation. They are synthesized so that they can be used to block disease processes by altering the synthesis of a specific protein. ASOs offers promising treatment options for a range of medical disorders. They facilitate the development of therapeutics affecting protein targets which cannot be treated with protein therapeutics. They can target a particular malfunctioning